Cepheid Q3 Revenues Grow 10 Percent as Firm Misses Estimates on Top, Bottom Lines | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid reported after the close of the market Tuesday a 10 percent spike in third quarter revenues as the firm missed analysts' consensus estimates on both the top and bottom lines due primarily to lower-than-expected gross margin.

The firm also announced that the US Food and Drug Administration has approved its assay for Trichomonas vaginalis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Sponsored by

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.